Lansoprazole Compared With Ranitidine for the Treatment of Nonerosive Gastroesophageal Reflux Disease
Open Access
- 26 June 2000
- journal article
- clinical trial
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 160 (12) , 1803-1809
- https://doi.org/10.1001/archinte.160.12.1803
Abstract
GASTROESOPHAGEAL reflux disease (GERD) is a ubiquitous, chronic disorder that may cause a significant decrease in patient functioning and quality of life and an increase in the risk for esophageal damage. While a large percentage of individuals report occasional or monthly heartburn,1 approximately 20% of the US adult population experiences reflux symptoms on a weekly basis.2 A recent study found that the presence of weekly heartburn symptoms has a significant negative impact on patients' physical and mental functioning.1This publication has 7 references indexed in Scilit:
- Symptomatic Gastroesophageal Reflux as a Risk Factor for Esophageal AdenocarcinomaNew England Journal of Medicine, 1999
- The comparative effects of lansoprazole, omeprazole, and ranitidine in suppressing gastric acid secretionClinical Therapeutics, 1997
- Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: A meta-analysisGastroenterology, 1997
- Lansoprazole 30 mg daily versus ranitidine 150 mg b.d. in the treatment of acid‐related dyspepsia in general practiceAlimentary Pharmacology & Therapeutics, 1997
- Twenty‐four‐hour intragastric acidity: 300 mg ranitidine b.d., 20 mg omeprazole o.m., 40 mg omeprazole o.m. vs. placeboAlimentary Pharmacology & Therapeutics, 1995
- Symptoms and Disease Severity in Gastro-Oesophageal Reflux DiseaseScandinavian Journal of Gastroenterology, 1994
- Appropriate Acid Suppression for the Management of Gastro-Oesophageal Reflux DiseaseDigestion, 1992